NuCana (NCNA) Projected to Post Earnings on Thursday

NuCana (NASDAQ:NCNA) is anticipated to announce its results before the market opens on Thursday, March 19th. Analysts expect the company to announce earnings of ($2.6944) per share for the quarter.

NuCana Price Performance

Shares of NCNA opened at $1.95 on Thursday. The firm has a 50 day simple moving average of $2.66 and a two-hundred day simple moving average of $3.51. NuCana has a one year low of $1.90 and a one year high of $268.00. The company has a market cap of $58,500.00, a P/E ratio of -0.01 and a beta of 1.69.

Analyst Ratings Changes

Several equities analysts have recently issued reports on NCNA shares. Wall Street Zen upgraded NuCana from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NuCana in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

NuCana Company Profile

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.